BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Go back to BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.33 +0.43 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.90 | 52 Week High | $108.96 | |||
| Open | $55.80 | 52 Week Low | $62.12 | |||
| Day High | $56.73 | P/E | N/A | |||
| Day Low | $55.74 | EPS | $-1.27 | |||
| Volume | 378,709 | |||||
